Cancer

Comprehend Systems Appoints New CEO in Response to Surging Demand for Clinical Intelligence Solutions; Enterprise Growth Expert to Scale Company and Expand Partner Ecosystem

November 20, 2017

Redwood City, Calif., November 13, 2017—Comprehend Systems, Inc., the leader in Clinical Intelligence solutions, has named Terry Cunningham CEO.  Cunningham will focus on scaling Comprehend in response to explosive customer demand for solutions that reduce time and risk in clinical trials. Cunningham will also drive expanded partner programs to help sponsors achieve faster, better clinical […]

Amgen, Merck, Roche get in on Syapse’s $30M round

November 16, 2017

by Amirah Al Idrus Syapse picked up $30 million in series D financing, funds it will use to bring its oncology precision medicine software to more healthcare providers. In addition to its oncology software platform, which enables caregivers in large health systems to practice precision medicine consistently, Syapse offers a data-sharing network. This provides physicians […]

US Dept. of Veterans Affairs Renews and Expands Cancer Testing Contract with Personal Genome Diagnostics

November 13, 2017

–-PGDx’s Pan-Cancer Profiling Panels with MSI Testing for Immuno-Oncology Applications Are Now Available Nationwide to Cancer Patients Treated at the VA–                                                                                                   –PGDx’s CancerSELECTTM 125 Offers Comprehensive Tissue-Based Tumor Profiling and Its PlasmaSELECTTM 64 Is First Liquid Biopsy Assay Available to Patients at VA Facilities— BALTIMORE, MD –Personal Genome Diagnostics Inc. (PGDx) today announced the renewal […]

Cmed to Demonstrate how encapsia® Transforms Clinical Trial Data Management, Capture and Reporting at Leading Oncology Meetings

November 13, 2017

HORSHAM, UK — November 13, 2017 – Cmed, an oncology focused, innovative technology-led CRO, today announced that it will showcase its encapsia® clinical data suite at two leading oncology meetings, Clinical Operations in Oncology Trials Europe, taking place 5-6 December in Munich, Germany, and the ASH Annual Meeting, taking place 9-12 December in Atlanta, GA. […]

Novartis Takes Fight to Pfizer’s Ibrance With New Kisqali Data

November 9, 2017

ZURICH (Reuters) – New data from Novartis’s breast cancer drug Kisqali underscored its effectiveness in pre-menopausal women, the Swiss drugmaker said, amid efforts to muscle in on turf dominated by rival Pfizer’s Ibrance. A late-stage trial showed Kisqali, in concert with hormonal therapies, halted the advance of hormone-receptor positive, human epidermal growth factor receptor-2 negative […]

CluePoints Builds on Late Phase work in Japan and Launches Risk-Based Monitoring Roadshow in Tokyo

November 8, 2017

Wayne, PA – CluePoints, a leading provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions for clinical trials, has further expanded its Late Phase work in Japan by entering into two new partnerships with global top 20 pharmaceutical companies. The collaborations mark the latest success for CluePoints in the region, with its centralized statistical […]

Bioclinica Acquires MDDX Research & Informatics Combining Advanced Image Management Cloud Technology with Its Scientific and Medical Imaging Leadership

November 7, 2017

Best-in-class solution ensures sponsors and CROs have global access to efficient, accurate, and scalable medical imaging to drive better data and outcomes DOYLESTOWN, Pa., Nov. 6, 2017 – Bioclinica®, the world-leading provider of scientific-enabled Medical Imaging, eHealth, and patient-centric solutions supporting clinical research, today announces it has acquired Silicon Valley-based MDDX Research & Informatics, adding […]

US FDA Approves AstraZeneca’s CALQUENCE® (acalabrutinib) For Adult Patients with Previously-Treated Mantle Cell Lymphoma

November 1, 2017

US FDA APPROVES ASTRAZENECA’S CALQUENCE® (acalabrutinib) FOR ADULT PATIENTS WITH PREVIOUSLY-TREATED MANTLE CELL LYMPHOMA Accelerated approval of Bruton tyrosine kinase (BTK) inhibitor in MCL marks AstraZeneca’s entry into the treatment of blood cancers 80% of patients receiving CALQUENCE achieved an overall response, with 40% achieving a complete response (WILMINGTON, Del., October 31, 2017) – AstraZeneca […]

Asana BioSciences to Present Updates on its Oncology Development Pipeline at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 25, 2017

Asana BioSciences, LLC, an oncology focused, clinical stage biopharmaceutical company, today announced that it will present updates regarding three of its lead molecules at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Philadelphia, PA, October 26-30, 2017. “We are very pleased with the progress made in advancing our oncology […]

Queen’s University Belfast in Collaboration with Almac Group Lead Largest Study of its Kind to Transform Prostate Cancer Treatment

October 24, 2017

Queen’s University Belfast have led the world’s largest research study using a diagnostic test developed by Almac Diagnostics, to better understand the biology of prostate cancer tumours, which could lead to a transformation in how prostate cancer is diagnosed and treated. Whether a prostate cancer patient has a slow-growing or aggressive tumour will affect the […]

The Foundation for Women’s Cancer and TESARO Announce 2nd Year of Partnership Supporting the National Race to End Women’s Cancer

October 18, 2017

CHICAGO and WALTHAM, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) — The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology, and TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the continuation of their partnership supporting the annual National Race to End Women’s Cancer. TESARO is the Presenting Break-Through Sponsor […]

Digitizing Clinical Research Processes – The New Frontier

October 6, 2017

One in three people will be diagnosed with cancer in their lifetime, but according to the NIH, only 3-5% of adult cancer patients participate in clinical trials. Advancing therapies in oncology and other disease areas is at the forefront of academic and commercial R&D. But enrollment and site initiation is often hindered by daunting, time […]

Caregivers Wish Liver Cancer Received Greater Public Awareness in the U.S., New Survey Reveals

October 4, 2017

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY), in collaboration with Blue Faery: The Adrienne Wilson Liver Cancer Association, a leading liver cancer patient advocacy organization, today announced the findings from a new survey exploring the experiences of caregivers of people living with early or advanced stage liver cancer in the U.S. According to the caregivers surveyed, […]

Bioinformatics Points The Way To Treating Deadly Pancreatic Cancer

September 28, 2017

By Adam Hadhazy  A new study that sifted through an enormous mass of biomolecular data has significantly advanced our understanding of the genetics of pancreatic cancer and opened up promising treatment avenues. More than 40,000 Americans die each year from this devastating disease, making it the third deadliest cancer nationwide. Most patients do not show […]

FEEDBACK